UNLABELLED: Systemic levels of interferon-gamma-inducible protein-10 (IP-10) are predictive of treatment-induced clearance in chronic hepatitis C virus (HCV). In the present study, factors associated with plasma IP-10 levels at the time of acute HCV detection and the association between IP-10 levels and spontaneous clearance were assessed in three cohorts of acute HCV infection. Among 299 individuals, 245 (181 male, 47 human immunodeficiency virus-positive [HIV+]) were HCV RNA+ at acute HCV detection. In adjusted analysis, factors independently associated with IP-10 levels ≥150 pg/mL (median level) included HCV RNA levels >6 log IU/mL, HIV coinfection and non-Aboriginal ethnicity. Among 245 HCV RNA+ at acute HCV detection, 214 were untreated (n = 137) or had persistent infection (infection duration ≥26 weeks) at treatment initiation (n = 77). Spontaneous clearance occurred in 14% (29 of 214). Individuals without spontaneous clearance had significantly higher mean plasma IP-10 levels at the time of acute HCV detection than those with clearance (248 ± 32 versus 142 ± 22 pg/mL, P = 0.008). The proportion of individuals with spontaneous clearance was 0% (0 of 22, P = 0.048) and 16% (27 of 165) and in those with and without plasma IP-10 levels ≥380 pg/mL. In adjusted analyses, favorable IL28B genotype was associated with spontaneous clearance, while higher HCV RNA level was independently associated with lower odds of spontaneous clearance. CONCLUSION: High IP-10 levels at acute HCV detection were associated with failure to spontaneously clear HCV. Patients with acute HCV and high baseline IP-10 levels, particularly >380 pg/mL, should be considered for early therapeutic intervention, and those with low levels should defer therapy for potential spontaneous clearance. (HEPATOLOGY 2013;).
UNLABELLED: Systemic levels of interferon-gamma-inducible protein-10 (IP-10) are predictive of treatment-induced clearance in chronic hepatitis C virus (HCV). In the present study, factors associated with plasma IP-10 levels at the time of acute HCV detection and the association between IP-10 levels and spontaneous clearance were assessed in three cohorts of acute HCV infection. Among 299 individuals, 245 (181 male, 47 human immunodeficiency virus-positive [HIV+]) were HCV RNA+ at acute HCV detection. In adjusted analysis, factors independently associated with IP-10 levels ≥150 pg/mL (median level) included HCV RNA levels >6 log IU/mL, HIV coinfection and non-Aboriginal ethnicity. Among 245 HCV RNA+ at acute HCV detection, 214 were untreated (n = 137) or had persistent infection (infection duration ≥26 weeks) at treatment initiation (n = 77). Spontaneous clearance occurred in 14% (29 of 214). Individuals without spontaneous clearance had significantly higher mean plasma IP-10 levels at the time of acute HCV detection than those with clearance (248 ± 32 versus 142 ± 22 pg/mL, P = 0.008). The proportion of individuals with spontaneous clearance was 0% (0 of 22, P = 0.048) and 16% (27 of 165) and in those with and without plasma IP-10 levels ≥380 pg/mL. In adjusted analyses, favorable IL28B genotype was associated with spontaneous clearance, while higher HCV RNA level was independently associated with lower odds of spontaneous clearance. CONCLUSION: High IP-10 levels at acute HCV detection were associated with failure to spontaneously clear HCV. Patients with acute HCV and high baseline IP-10 levels, particularly >380 pg/mL, should be considered for early therapeutic intervention, and those with low levels should defer therapy for potential spontaneous clearance. (HEPATOLOGY 2013;).
Authors: Martin Lagging; Ana I Romero; Johan Westin; Gunnar Norkrans; Amar P Dhillon; Jean-Michel Pawlotsky; Stefan Zeuzem; Michael von Wagner; Francesco Negro; Solko W Schalm; Bart L Haagmans; Carlo Ferrari; Gabriele Missale; Avidan U Neumann; Elke Verheij-Hart; Kristoffer Hellstrand Journal: Hepatology Date: 2006-12 Impact factor: 17.425
Authors: Xiao-Song He; Xuhuai Ji; Matthew B Hale; Ramsey Cheung; Aijaz Ahmed; Yaqian Guo; Garry P Nolan; Lawrence M Pfeffer; Teresa L Wright; Neil Risch; Robert Tibshirani; Harry B Greenberg Journal: Hepatology Date: 2006-08 Impact factor: 17.425
Authors: Ana I Romero; Martin Lagging; Johan Westin; Amar P Dhillon; Lynn B Dustin; Jean-Michel Pawlotsky; Avidan U Neumann; Carlo Ferrari; Gabriele Missale; Bart L Haagmans; Solko W Schalm; Stefan Zeuzem; Francesco Negro; Elke Verheij-Hart; Kristoffer Hellstrand Journal: J Infect Dis Date: 2006-08-29 Impact factor: 5.226
Authors: Sandra Beinhardt; Judith H Aberle; Michael Strasser; Emina Dulic-Lakovic; Andreas Maieron; Anna Kreil; Karoline Rutter; Albert F Staettermayer; Christian Datz; Thomas M Scherzer; Robert Strassl; Martin Bischof; Rudolf Stauber; Gerd Bodlaj; Hermann Laferl; Heidemarie Holzmann; Petra Steindl-Munda; Peter Ferenci; Harald Hofer Journal: Gastroenterology Date: 2011-09-24 Impact factor: 22.682
Authors: Jason Grebely; Jesse D Raffa; Calvin Lai; Mel Krajden; Brian Conway; Mark W Tyndall Journal: Can J Gastroenterol Date: 2007-07 Impact factor: 3.522
Authors: Daniel S Fierer; Douglas T Dieterich; Michael P Mullen; Andrea D Branch; Alison J Uriel; Damaris C Carriero; Wouter O van Seggelen; Rosanne M Hijdra; David G Cassagnol Journal: Clin Infect Dis Date: 2013-12-13 Impact factor: 9.079
Authors: Behzad Hajarizadeh; Jason Grebely; Tanya Applegate; Gail V Matthews; Janaki Amin; Kathy Petoumenos; Margaret Hellard; William Rawlinson; Andrew Lloyd; John Kaldor; Gregory J Dore Journal: J Med Virol Date: 2014-07-08 Impact factor: 2.327
Authors: Christina C Chang; Megan Crane; Jingling Zhou; Michael Mina; Jeffrey J Post; Barbara A Cameron; Andrew R Lloyd; Anthony Jaworowski; Martyn A French; Sharon R Lewin Journal: Immunol Rev Date: 2013-07 Impact factor: 12.988